Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Real World Study of Classic Infectious Disease

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Odkaz je uložen do schránky
PostaveníNábor
Sponzoři
Huashan Hospital
Spolupracovníci
First Affiliated Hospital of Xinjiang Medical University
First Affiliated Hospital of Harbin Medical University
The ninth Hospital of NanChang city
Luoyang Central Hospital
Second Affiliated Hospital of Nanchang University
The Fifth Affiliated Hospital Xinjiang Medical University
LanZhou University
Huizhou Municipal Central Hospital
First Affiliated Hospital of Fujian Medical University
Fuzhou Municipal Infectious Diseases Hospital
Henan Provincial People's Hospital
The First Affiliated Hospital of Lanzhou Medical University
Linyi People's Hospital
Nantong University
Nanyang Central Hospital
Qilu Hospital of Shandong University
Qianfoshan Hospital
Infectious Hospital of Jining City
The Affiliated Hospital of Jining Medical University and Zaozhuang City
The First Affiliated Hospital of Shanxi Medical University
First Affiliated Hospital Xi'an Jiaotong University
People's Hospital of Xinjiang Uygur Autonomous Region
Yuncheng Central Hospital
Zibo Central Hospital
The Second Affiliated Hospital of Henan Medical University
West Hospital of the First Affiliated Hospital of Guangxi University
First Affiliated Hospital of Jilin University
The Affiliated Hospital of Xuzhou Medical University
The First Affiliated Hospital with Nanjing Medical University
The First Affiliated Hospital of Anhui Medical University
The Second Hospital of Shandong University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Klíčová slova

Abstraktní

This study aimed to collect and analyze clinical specimens of patients with classic infectious diseases in the real world. To investigate the epidemiological distribution of classic infectious diseases (brucellosis, epidemic hemorrhagic fever, kala-azar) and treatment options suitable for China.

Popis

Brucellosis is present in humans and animals in nearly 170 countries and regions around the world. In the 1950s and 1960s, brucellosis was seriously prevalent in China. In the 1970s, the epidemic gradually declined. It was basically controlled in the 1980s and early 1990s, but since the mid-1990s, the epidemic has continued to rise rapidly, and brucellosis It has become one of the fastest infectious diseases reporting the rising incidence rate. In 2016, 47,139 cases were reported, with an incidence rate of 3.44/100,000. The provinces with the most reported cases are Xinjiang Uygur Autonomous Region, Inner Mongolia Autonomous Region, Shanxi Province and Heilongjiang Province. However, in the southern non-pastoral areas of Guangdong Province and Guangxi Province, brucellosis outbreaks have occurred in recent years, and the incidence rates in Henan and Fujian provinces have continued to rise.

Hemorrhagic fever with renal syndrome, also known as epidemic hemorrhagic fever, is an infectious disease caused by the Hantavirus. The main clinical features are fever, exudation, hemorrhage, hypotensive shock, and kidney damage. It was once epidemic viral infection in China after viral hepatitis. In the 1980s, the number of cases reported exceeded 100,000. More than 1650,000 patients have been reported in China since 1950, including more than 47,000 deaths, with a total case fatality rate of approximately 2.89%. The number of people in the province accounted for more than 80% of the total number of people in the country. From 2004 to 2015, Shaanxi Province and the three northeastern provinces were the hardest hit areas of national hemorrhagic fever.

There are reports of sporadic leishmaniasis in China, but they are rare and lack corresponding epidemiological data. In 2015, 507 new cases of visceral leishmaniasis were reported, which was a high level in the past 10 years. However, the incidence rate remains at a low level of 0.0372/100,000. In recent years, visceral leishmaniasis is mainly distributed in the northwestern part of China, and there are many cases reported in the southwestern part of the country. The three areas with the highest incidence rate are Xinjiang Uygur Autonomous Region, Gansu Province and Sichuan Province. The cases in non-endemic areas are mainly adults who go to work in popular areas, and mainly male physical workers, while the popular areas are mainly infants and young children.

Termíny

Poslední ověření: 04/30/2020
První předloženo: 07/05/2019
Odhadovaná registrace vložena: 07/14/2019
První zveřejnění: 07/15/2019
Poslední aktualizace byla odeslána: 05/12/2020
Poslední aktualizace zveřejněna: 05/13/2020
Aktuální datum zahájení studie: 05/12/2020
Odhadované datum dokončení primární: 05/31/2024
Odhadované datum dokončení studie: 05/31/2029

Stav nebo nemoc

Brucelloses
Epidemic Hemorrhagic Fever
Kala-Azar

Intervence / léčba

Drug: Antibiotics

Fáze

-

Skupiny zbraní

PažeIntervence / léčba
kala-azar group
epidemic hemorrhagic fever group
brucellosis group

Kritéria způsobilosti

Věky způsobilé ke studiu 18 Years Na 18 Years
Pohlaví způsobilá ke studiuAll
Metoda vzorkováníProbability Sample
Přijímá zdravé dobrovolníkyNe
Kritéria

Inclusion Criteria:

Brucellosis: Patients with any of the following confirmed the evidence.

1. sample culture: Brucella;

2. Specific antigen or antibody (IgG or IgM) positive. epidemic hemorrhagic fever:

1 specific antibody positive 2 Hantavirus RNA positive kala-azar:

1. latent infection: rK39 antibody positive

2. patients with the following evidence of kala-azar diagnosis: 1) bone marrow, spleen puncture sample culture: Leishmania; 2) bone marrow, spleen puncture sample smear: Leishmania; 3) clinical symptoms, history of exposure or epidemiology, and positive screening test (rK39 positive)

Exclusion Criteria:

1. Patient history data is incomplete

2. HIV antibody positive and AIDS patients

3. Patients who participated in other clinical trials during the same period.

4. Pregnant, lactating women or women of childbearing age who are ready to conceive.

Výsledek

Primární výsledná opatření

1. Number of patients With Prevalence Rate of specific infectious diseases(brucellosis, epidemic hemorrhagic fever, and kala-azar) [1 day]

Měření sekundárních výsledků

1. Number of Participants With Successful Treatment of specific antibiotic therapy. [30 days]

2. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [2 years]

Připojte se k naší
facebookové stránce

Nejúplnější databáze léčivých bylin podložená vědou

  • Funguje v 55 jazycích
  • Bylinné léky podporované vědou
  • Rozpoznávání bylin podle obrázku
  • Interaktivní mapa GPS - označte byliny na místě (již brzy)
  • Přečtěte si vědecké publikace související s vaším hledáním
  • Hledejte léčivé byliny podle jejich účinků
  • Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty

Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu

Google Play badgeApp Store badge